ValsecchiAAConteCFioreNM, et al.Press releases of industrysponsored clinical trials in oncology: characteristics, timing and financial impact. J Cancer Policy2025 Apr 21; 44: 100587.
2.
ForrestRLagardeMAggarwalA,et al.Preferences for speed of access versus certainty of the survival benefit of new cancer drugs: a discrete choice experiment. Lancet Oncol2024 Dec; 25: 1635–1643.
3.
MeropolNJEglestonBLBuzagloJS, et al.CONNECT Study Research Group. Cancer patient preferences for quality and length of life. Cancer2008 Dec 15; 113: 3459–3466.
4.
WilliamsCPMiller-SonetENippRD, et al.Importance of quality-oflife priorities and preferences surrounding treatment decision making inpatients with cancer and oncology clinicians. Cancer2020 Aug 1; 126: 3534–3541.
5.
YongASJLimKKFox-RushbyJ, et al.A longitudinal evaluation of the preferences of patients with advanced cancer for quality of life and survival in Malaysia: a discrete choice experiment. Value Health2023 Dec; 26: 1772–1781.
6.
ShresthaAMartinCBurtonM, et al.Quality of life versus length of life considerations in cancer patients: a systematic literature review. Psychooncology2019 Jul; 28: 1367–1380.
7.
DavisCNaciHGurpinarE, et al.Availability of evidence of benefits on overall survival and quality of life of cancer drugs approved by European Medicines Agency: retrospective cohort study of drug approvals 2009–13. Br Med J2017; 359: j4530.
8.
SacristánJALizanLComellasM, et al.Perceptions of oncologists, healthcare policy makers, patients and the general population on the value of pharmaceutical treatments in oncology. Adv Ther2016 Nov; 33: 2059–2068.
9.
Vallejo-TorresLVannessDJPauldenM,et al.The opportunity cost of funding new medicines: an attempt to measure the invisible. Gac Sanit2025 Mar 6; 39: 102460.
10.
KooleSNHuismanAHTimmersL, et al.Lessons learned from postmarketing withdrawals of expedited approvals for oncology drug indications. Lancet Oncol2024 Mar; 25: e126–e135.
